This study is testing a treatment plan for pancreatic cancer that can be removed by surgery. The treatment uses three drugs: gemcitabine, cisplatin, and nab-paclitaxel given before surgery, which is called neoadjuvant therapy. These drugs are chemotherapy medicines. Gemcitabine stops cancer cells from making DNA, which is needed for them to grow. Cisplatin is a platinum-containing drug that kills cancer cells, while nab-paclitaxel stops cancer cells from dividing. The goal is to see if using these drugs before surgery helps patients live longer. Patients will receive the drugs through a vein (IV) on specific days and will be monitored for two years after treatment.

• Treatment lasts for up to 4 cycles, each cycle being 28 days long.
• Patients must be adults and able to follow the study schedule.
• There are specific health criteria to join, such as good blood counts and no major health problems.

Patients will have regular check-ups to monitor their health and cancer status. It's important to understand that there are risks, like side effects from the drugs, and not everyone will be eligible to participate.